SCHEDULE 13G/A: Titan Trust 2024 I Discloses 9.99% Passive Stake in DarioHealth Corp.

Titan Trust 2024 I has reported a 9.99% beneficial ownership stake in DarioHealth Corp., primarily through common stock and warrants, as detailed in an amended Schedule 13G filing.

Summary

• Titan Trust 2024 I, a Delaware statutory trust, has filed an Amendment No. 1 to Schedule 13G, disclosing its beneficial ownership in DarioHealth Corp.
• The reporting person, Titan Trust 2024 I, beneficially owns an aggregate of 3,960,685 shares of DarioHealth Corp. common stock.
• This ownership represents 9.99% of the class of securities.
• The total beneficial ownership consists of 2,499,828 shares of common stock issued on November 14, 2024, upon cashless exercise of a warrant dated February 15, 2024.
• Additionally, it includes 1,460,857 shares of common stock issuable under a separate warrant dated February 15, 2024, which is exercisable within 60 days of December 11, 2024.
• The warrant contains a customary 9.99% blocker provision, preventing Titan Trust 2024 I and its affiliates from exercising the warrant to the extent that their beneficial ownership would exceed 9.99% of the common stock.
• The percentage ownership was calculated based on 38,185,640 shares of common stock outstanding as of December 9, 2024, plus the 1,460,857 shares issuable from the warrant.
• WhiteHawk Capital Partners LP, as the Administrator of Titan Trust 2024 I, may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing (Schedule 13G/A) disclosing passive beneficial ownership. It does not contain operational or financial performance updates that would typically influence sentiment positively or negatively, beyond confirming a significant, passive investor stake.

Positives

• Titan Trust 2024 I holds a significant 9.99% beneficial ownership in DarioHealth Corp., indicating a notable investment.
• The inclusion of a 9.99% blocker provision suggests a passive investment strategy, potentially reducing concerns about immediate control changes and signaling stability.

Negatives

• No specific negative information was disclosed in this Schedule 13G filing.

Risks

• The 9.99% blocker provision in the warrant limits Titan Trust 2024 I's ability to increase its beneficial ownership beyond this threshold without further disclosures or changes to the agreement, which could cap potential future investment from this entity.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from DarioHealth Corp. regarding its future outlook.

Management Comments

• This Schedule 13G filing is a disclosure by Titan Trust 2024 I and does not contain direct management comments from DarioHealth Corp.

Industry Context

This Schedule 13G filing primarily concerns a change in beneficial ownership and does not provide specific industry context or trends related to DarioHealth Corp.'s operations.

Comparison to Industry Standards

• This filing is a regulatory disclosure of beneficial ownership and does not contain information suitable for comparison to industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive investor's stake, potentially offering some stability by indicating a long-term, non-activist interest.

Next Steps

• The document is a beneficial ownership disclosure and does not outline specific future actions or milestones for DarioHealth Corp.

Key Dates

Keywords

DarioHealth Corp., Titan Trust 2024 I, Schedule 13G, beneficial ownership, common stock, warrants, SEC filing, passive investment, WhiteHawk Capital Partners, equity stake